Related Articles
Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer
ALK‑positive locally advanced lung cancer in a patient who achieved long‑term complete response with crizotinib: A case report
Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report
Successful oral desensitization with crizotinib after crizotinib‑induced hepatitis in an anaplastic lymphoma kinase‑rearranged non‑small‑cell lung cancer patient: A case report
ALK inhibitors and advanced non-small cell lung cancer (Review)